Table 1. Summary of Optical Agents Reported in Human Clinical Imaging Trials.

optical imaging agent	condition	trial number	clinical stage
methylene blue	small intestine neuroendocrine tumors	NL9305a
5-ALA	glioma	NCT01116661	phase 2
OTL-38	ovarian cancer	NCT02317705	phase 2
	neoplasms	NCT02602119	phase 1
	ovarian cancer	2013-004774-10b	phase 1
		2014-002352-12b
	neoplasms, pituitary neoplasms	NCT02629549	phase 1
EM-137	Barrett’s esophagus, esophageal cancer, dysplasia in Barrett’s esophagus	NCT03205501	phase 1
cRGD-ZW800-1	colon cancer	2017-002772b	phase 1 and phase 2
	respiratory infections	NCT02491164	phase 1
AVB-620	breast cancer	NCT02391194	phase 1
cetuximab-IRDye800CW	head and neck cancer	NCT01987375	phase 1
panitumumab-IRDye800CW	pancreatic adenocarcinoma	NCT03384238	phase 1 and phase 2
LUM015	sarcoma, soft tissue sarcoma, breast cancer	NCT01626066	Phase 1
VGT-309	cathepsin activity in human pulmonary tumors	ACTRN12621000301864c	phase 1 and phase 2
PARPi-FL	oral squamous cell carcinoma	NCT03085147	phase 1 and phase 2
folate-FITC	ovarian cancer	NTR1980d
		EudraCT 2009-010559-29b
benvazucimab-800CW	breast cancer	NCT02583568	phase 1 and phase 2
colon KCC heptapeptide	colon polyps, colorectal cancer, inflammatory bowel disease (IBD)	NCT02156557	phase 1
FITC-adalimumab	Crohn’s disease	NCT01275508	phase 1 and phase 2

^aICTRP registration code.

^bEuropean Clinical Trials Database.

^cAustralian New Zealand Clinical Trials Registry.

^dDutch Trial Register.